Repligen | RGEN - Des Atouts





Des Atouts Changement Date
Agilent USD 13.97B 902M 2026-06
Align Technology USD 6.52B 103.03M 2026-09
Bio Techne USD 2.59B 36.12M 2026-06
BioMarin Pharmaceutical USD 11.57B 154.21M 2026-09
Bristol-Myers Squibb USD 88.77B 1.14B 2026-09
Bruker USD 6.05B 77.8M 2026-06
Charles River Laboratories USD 7.45B 80.64M 2026-09
Danaher USD 93.28B 914M 2026-09
Dentsply International USD 5.2B 25M 2026-06
General Electric Aerospace USD 127.2B 477M 2026-09
Henry Schein USD 11.51B 129M 2026-09
Illumina USD 6.81B 162M 2026-09
IQVIA Holdings USD 30.47B 593M 2026-09
Mettler Toledo International USD 3.67B 2.03M 2026-06
Myriad Genetics USD 638.9M 34.8M 2026-06
OraSure Technologies USD 360.55M 18.62M 2026-06
Pacific Biosciences Of California USD 751.85M 30.51M 2026-06
Pfizer USD 204.54B 3.41B 2026-09
Repligen USD 2.93B 23.77M 2026-09
Revvity USD 11.49B 555.49M 2026-09
Standard Biotools USD 635.33M 8.11M 2026-09
Thermo Fisher Scientific USD 114.23B 1.06B 2026-09
Waters USD 24.12B 636M 2026-09
West Pharmaceutical Services USD 4.06B 15.7M 2026-09